FDA Approves New Prostate Cancer Imaging Agent Gozellix®
March 21, 2025 | 07:38
Telix Pharmaceuticals Limited today announces that the United States Food and Drug Administration has approved its New Drug Application for Gozellix® gozetotide injection), Telix's next-generation PSMA-PET imaging agent for prostate cancer.
Mobile Version